FOXP3 and head and neck squamous cell carcinoma: Thus, FoxP3+ Tregs were associated with favourable prognosis in patients with Hodgkin or follicular lymphoma as well as in HNSCC patients [16,24,28], while no effect was reported for anal carcinomas [23].